Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, A. M. K.
Right arrow Articles by Wahl, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, A. M. K.
Right arrow Articles by Wahl, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2789-2795, 2002
© 2002 by the American Diabetes Association, Inc.

Differential Interactions of Nateglinide and Repaglinide on the Human ß-Cell Sulphonylurea Receptor 1

Ann Maria K. Hansen1, Inge T. Christensen1, John Bondo Hansen1, Richard D. Carr1, Frances M. Ashcroft2, and Philip Wahl1

1 Discovery, Novo Nordisk A/S, Bagsvaerd, Denmark
2 University Laboratory of Physiology, Oxford University, Oxford, U.K.

Repaglinide and nateglinide represent a new class of insulin secretagogues, structurally unrelated to sulphonylureas, that were developed for the treatment of type 2 diabetes. The inhibitory effect of these drugs was investigated on recombinant wild-type and mutant Kir6.2/SUR1 channels expressed in HEK293 cells. Nateglinide and repaglinide dose-dependently inhibited whole-cell Kir6.2/SUR1 currents with half-maximal inhibitory concentration (IC50) values of 800 and 21 nmol/l, respectively. Mutation of serine 1237 in SUR1 to tyrosine (S1237Y) abolished tolbutamide and nateglinide block, suggesting that these drugs share a common point of interaction on the SUR1 subunit of the ATP-sensitive K+ channel. In contrast, repaglinide inhibition was unaffected by the S1237Y mutation (IC50 = 23 nmol/l). Radioligand binding studies revealed a single high-affinity binding site for [3H]repaglinide on membranes prepared from HEK293 cells expressing wild-type (equilibrium dissociation constant [KD] = 0.40 nmol/l) or mutant (KD = 0.31 nmol/l) Kir6.2/SUR1 channels. Nateglinide and tolbutamide displaced [3H]repaglinide binding to wild-type channels with IC50 values of 0.7 and 26 µmol/l, respectively, but produced <10% displacement of [3H]repaglinide bound to mutant channels. This is consistent with the idea that binding of nateglinide and tolbutamide, but not repaglinide, is abolished by the SUR1[S1237Y] mutation and that the binding site for repaglinide is not identical to that of nateglinde/tolbutamide. These results are discussed in terms of a conformational analysis of the drug molecules.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Winkler, D. Stephan, S. Bieger, P. Kuhner, F. Wolff, and U. Quast
Testing the Bipartite Model of the Sulfonylurea Receptor Binding Site: Binding of A-, B-, and A + B-Site Ligands
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 701 - 708.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
W. H. Vila-Carriles, G. Zhao, and J. Bryan
Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels
FASEB J, January 1, 2007; 21(1): 18 - 25.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Nagamatsu, M. Ohara-Imaizumi, Y. Nakamichi, T. Kikuta, and C. Nishiwaki
Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules.
Diabetes, October 1, 2006; 55(10): 2819 - 2825.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
N. H McClenaghan, P. R Flatt, and A. J Ball
Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
J. Endocrinol., September 1, 2006; 190(3): 889 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Tuomi, E. H. Honkanen, B. Isomaa, L. Sarelin, and L. C. Groop
Improved Prandial Glucose Control With Lower Risk of Hypoglycemia With Nateglinide Than With Glibenclamide in Patients With Maturity-Onset Diabetes of the Young Type 3
Diabetes Care, February 1, 2006; 29(2): 189 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Shiota, J. V. Rocheleau, M. Shiota, D. W. Piston, and M. A. Magnuson
Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor
Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E570 - E577.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Maedler, R. D. Carr, D. Bosco, R. A. Zuellig, T. Berney, and M. Y. Donath
Sulfonylurea Induced {beta}-Cell Apoptosis in Cultured Human Islets
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 501 - 506.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
U. Quast, D. Stephan, S. Bieger, and U. Russ
The Impact of ATP-Sensitive K+ Channel Subtype Selectivity of Insulin Secretagogues for the Coronary Vasculature and the Myocardium
Diabetes, December 1, 2004; 53(suppl_3): S156 - S164.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Aldhahi, J. Armstrong, C. Bouche, R. D. Carr, A. Moses, and A. B. Goldfine
{beta}-Cell Insulin Secretory Response to Oral Hypoglycemic Agents Is Blunted in Humans in Vivo during Moderate Hypoglycemia
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4553 - 4557.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Rosenstock, D. R. Hassman, R. D. Madder, S. A. Brazinsky, J. Farrell, N. Khutoryansky, and P. M. Hale
Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study
Diabetes Care, June 1, 2004; 27(6): 1265 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Ostergard, K. B. Degn, M.-A. Gall, R. D. Carr, J. D. Veldhuis, M. K. Thomsen, R. A. Rizza, and O. Schmitz
The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 297 - 302.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Chachin, M. Yamada, A. Fujita, T. Matsuoka, K. Matsushita, and Y. Kurachi
Nateglinide, a D-Phenylalanine Derivative Lacking Either a Sulfonylurea or Benzamido Moiety, Specifically Inhibits Pancreatic beta -Cell-Type KATP Channels
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1025 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. G. Straub, J. Mulvaney-Musa, H. Yajima, G. A. Weiland, and G. W.G. Sharp
Stimulation of Insulin Secretion by Denatonium, One of the Most Bitter-Tasting Substances Known
Diabetes, February 1, 2003; 52(2): 356 - 364.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Proks, F. Reimann, N. Green, F. Gribble, and F. Ashcroft
Sulfonylurea Stimulation of Insulin Secretion
Diabetes, December 1, 2002; 51(90003): S368 - 376.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.